Bio Plus Co., Ltd (KOSDAQ:099430)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,230.00
-60.00 (-0.82%)
Jul 18, 2025, 3:30 PM KST
16.80%
Market Cap425.64B
Revenue (ttm)79.78B
Net Income (ttm)19.60B
Shares Out58.87M
EPS (ttm)333.28
PE Ratio21.69
Forward PEn/a
Dividend50.00 (0.69%)
Ex-Dividend DateDec 27, 2024
Volume580,117
Average Volume336,431
Open7,290.00
Previous Close7,290.00
Day's Range7,040.00 - 7,340.00
52-Week Range4,385.00 - 8,420.00
Beta0.52
RSI52.11
Earnings DateAug 14, 2025

About Bio Plus

Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; S... [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 2003
Employees 121
Stock Exchange KOSDAQ
Ticker Symbol 099430
Full Company Profile

Financial Performance

In 2024, Bio Plus's revenue was 66.41 billion, an increase of 2.10% compared to the previous year's 65.04 billion. Earnings were 14.15 billion, a decrease of -44.68%.

Financial Statements

News

There is no news available yet.